DOI: https://dx.doi.org/10.18565/pharmateca.2024.1.192-196
Милованов С.С.
ИП «Милованов Святослав Сергеевич», Москва, Россия
1. Kibby M. Patient recruitment feasibility. Appl Clin Trails. 2011;20(6):80–7. 2. Redeker С., Hanson D. Optimizing Patient Recruitment and Engagement Strategies June 9, 2022. URL: https://www.appliedclinicaltrialsonline.com/view/optimizing-patient-recruitment-and-engagement-strategies (last access: 01.08.2022). 3. Fogel D.B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contempor ClinTrial Communicat. 2018;11:156–64. 4. Lievre M. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility Commentary: Early discontinuation violates Helsinki principles. BMJ. 2001;322(7286):603–6. Doi: 10.1136/bmj.322.7286.603. 5. McDonald A.M., Knight R.C., Campbell M.K., et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;7(9). Doi: 10.1186/1745-6215-7-9. 6. Levett K.M., Roberts C.L., Simpson J.M., Morris J.M. Site-specific predictors of successful recruitment to a perinatal clinical trial. Clin Trials. 2014;11:584–89. 7. Bieganek C., Aliferis C., Ma S. Prediction of clinical trial enrollment rates. PLoS One. 2022;17(2):e0263193. Doi: 10.1371/journal.pone.0263193. 8. Prediction of Recruitment Potential of Participating Centers in Clinical Trials by Standardized Translation of Selection Criteria and Queries From DRG Database (Pred-Inclus). URL: https://clinicaltrials.gov/ct2/show/NCT03019068 (last access: 01.10.2022). 9. Gross D. A research agenda for understanding participation in clinical research. Res Nurs Health. 2006;29(3):172–75. Doi: 10.1002/nur.20135. 10. Бестужев-Лада И.В. Впереди XXI век: перспективы, прогнозы, футурологии. Антология современной классической прогностики 1959–1999. М., 2000. 480 с. 11. Саватеев А.В., Белоцерковский М.В., Мосчиц-ка К., Палумбо Д. Оценка физибильности как краеугольный камень успешного клинического исследования. Качественная клиническая практика. 2013;2:37–46. 12. van den Bora R.M., Grobbeea D.E., Oostermana B.J., et al. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contempor. Clin Trial Communicat. 2017;7:208–16. 13. Getz K., Predicting successful site performance, Appl Clin Trials. 2011;20(11). URL: http://www.appliedclinicaltrialsonline.com/predicting-successful-siteperformance (last access: 02.07.2022). 14. Dane A., Ashraf S., Timmis J., et al. Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives. BMJ. Open 2022;12:e055165. Doi: 10.1136/bmjopen-2021-055165. 15. Yang E., O’Donovan C., Phillips J., et al. Quantifying and visualizing site performance in clinical trials. Contempor Clin Trial Communicat. 2018;9:108–14. Doi: 10.1016/j.conctc.2018.01.005. 16. Haidich A.-B. Late-Starter Sites in Randomized Controlled Trials. J Clin Epidemiol. 2003;56(2003):408–15.
Автор для связи: Святослав Сергеевич Милованов, к.м.н., ИП «Милованов Святослав Сергеевич», Москва, Россия; milovanovss@gmail.com; ORCID: https://orcid.org/0000-0001-9843-6096, eLibrary SPIN: 156131; Scopus Author ID: 58575569000; ResearcherID - ACK-8622-2022